Clinical Trial

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.
Protocol Amendment History 3 changes
notable Primary completion pushed: 2028-04-19 -> 2029-12-03 2026-07-30
minor Completion pushed: 2030-03-05 -> 2030-05-30 2026-07-30
notable Trial sites expanded: 2 -> 5 locations 2026-04-04
Trial Details
NCT Number NCT07234942
Lead Sponsor Hoffmann-La Roche
Conditions Alzheimer's Disease
Enrollment 50 participants
Start Date 2026-01-27
Primary Completion 2029-12-03 (estimated)
Study Completion 2030-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-29